http://orcid.org/0000-0002-5784-3610
Citations (88)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Yiqi Fan & Shuai He. (2022) The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer. Cancer Management and Research 14, pages 1-17.
Read now
Read now
Liqi Li, Hu Huang, Mingjie Zhu & Junqiang Wu. (2021) Identification of Hub Genes and Pathways of Triple Negative Breast Cancer by Expression Profiles Analysis. Cancer Management and Research 13, pages 2095-2104.
Read now
Read now
Mobina Jalalvand, Farzaneh Darbeheshti & Nima Rezaei. (2021) Immune Checkpoint Inhibitors: Review of the Existing Evidence and Challenges in Breast Cancer. Immunotherapy 13:7, pages 587-603.
Read now
Read now
Rodrigo Kern, Stephany Christiane Correa, Thalita Basso Scandolara, Janaína Carla da Silva, Bruno Ricardo Pires & Carolina Panis. (2020) Current Advances in the Diagnosis and Personalized Treatment of Breast Cancer: Lessons from Tumor Biology. Personalized Medicine 17:5, pages 399-420.
Read now
Read now
Wan Qin, Jun Zou, Yongbiao Huang, Chaofan Liu, Yalin Kang, Hu Han, Yang Tang, Long Li, Bo Liu, Weiheng Zhao & Xianglin Yuan. (2020) Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice. OncoImmunology 9:1.
Read now
Read now
Leland G. Richardson, Linda T. Nieman, Anat O. Stemmer-Rachamimov, Xijin S. Zheng, Khalifa Stafford, Hiroaki Nagashima, Julie J. Miller, Juri Kiyokawa, David T. Ting, Hiroaki Wakimoto, Daniel P. Cahill, Bryan D. Choi & William T. Curry. (2020) IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice. OncoImmunology 9:1.
Read now
Read now
Adam C. Mirando, Akash Patil, Christine I. Rafie, Brian J. Christmas, Niranjan B. Pandey, Vered Stearns, Elizabeth M. Jaffee, Evanthia T. Roussos Torres & Aleksander S. Popel. (2020) Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide. OncoImmunology 9:1.
Read now
Read now
Sangeeta K. Bisheshar, Emma J. De Ruiter, Lot A. Devriese & Stefan M. Willems. (2020) The prognostic role of NK cells and their ligands in squamous cell carcinoma of the head and neck: a systematic review and meta-analysis. OncoImmunology 9:1.
Read now
Read now
Sonja Bergmann, Anja Coym, Leonie Ott, Armin Soave, Michael Rink, Melanie Janning, Malgorzata Stoupiec, Cornelia Coith, Sven Peine, Gunhild von Amsberg, Klaus Pantel & Sabine Riethdorf. (2020) Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC). OncoImmunology 9:1.
Read now
Read now
Ieva Saulite, Desislava Ignatova, Yun-Tsan Chang, Christina Fassnacht, Florentia Dimitriou, Eleni Varypataki, Florian Anzengruber, Mirjam Nägeli, Antonio Cozzio, Reinhard Dummer, Julia Scarisbrick, Steve Pascolo, Wolfram Hoetzenecker, Malgorzata Bobrowicz & Emmanuella Guenova. (2020) Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation. OncoImmunology 9:1.
Read now
Read now
L. Faucheux, M. Grandclaudon, M. Perrot-Dockès, P. Sirven, F. Berger, A.S. Hamy, V. Fourchotte, A. Vincent-Salomon, F. Mechta-Grigoriou, F. Reyal, A. Scholer-Dahirel, M. Guillot-Delost & V. Soumelis. (2019) A multivariate Th17 metagene for prognostic stratification in T cell non-inflamed triple negative breast cancer. OncoImmunology 8:9.
Read now
Read now
I. M. H. Sønderstrup, M. B. Jensen, B. Ejlertsen, J. O. Eriksen, A. M. Gerdes, T. A. Kruse, M. J. Larsen, M. Thomassen & A. V. Laenkholm. (2019) Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer. Acta Oncologica 58:3, pages 363-370.
Read now
Read now
Articles from other publishers (76)
Tian Zhu, Steven M. Alves, Arianna Adamo, Xiaona Wen, Kevin C. Corn, Anastasia Shostak, Shereena Johnson, Nicholas D. Shaub, Shannon E. Martello, Benjamin C. Hacker, Antonio D'Amore, Rizia Bardhan & Marjan Rafat. (2024) Mammary tissue-derived extracellular matrix hydrogels reveal the role of irradiation in driving a pro-tumor and immunosuppressive microenvironment. Biomaterials 308, pages 122531.
Crossref
Crossref
Fokhrul Hossain, Deniz A. Ucar, Giulia Monticone, Yong Ran, Samarpan Majumder, Kristina Larter, Hanh Luu, Dorota Wyczechowska, Soroor Heidari, Keli Xu, Sudarvili Shanthalingam, Margarite Matossian, Yaguang Xi, Matthew Burow, Bridgette Collins-Burow, Luis Del Valle, Chindo Hicks, Jovanny Zabaleta, Todd Golde, Barbara Osborne & Lucio Miele. (2023) Sulindac sulfide as a non-immune suppressive γ-secretase modulator to target triple-negative breast cancer. Frontiers in Immunology 14.
Crossref
Crossref
Klara Geršak, Blaž Matija Geršak, Barbara Gazić, Andreja Klevišar Ivančič, Primož Drev, Nina Ružić Gorenjec & Cvetka Grašič Kuhar. (2023) The Possible Role of Anti- and Protumor-Infiltrating Lymphocytes in Pathologic Complete Response in Early Breast Cancer Patients Treated with Neoadjuvant Systemic Therapy. Cancers 15:19, pages 4794.
Crossref
Crossref
Samaneh Keshavarz, Jack R. Wall, Somayeh Keshavarz, Elham Vojoudi & Reza Jafari-Shakib. (2023) Breast cancer immunotherapy: a comprehensive review. Clinical and Experimental Medicine 23:8, pages 4431-4447.
Crossref
Crossref
Benjamin C. Hacker, Erica J. Lin, Dana C. Herman, Alyssa M. Questell, Shannon E. Martello, Rebecca J. Hedges, Anesha J. Walker & Marjan Rafat. (2023) Irradiated Mammary Spheroids Elucidate Mechanisms of Macrophage-Mediated Breast Cancer Recurrence. Cellular and Molecular Bioengineering 16:4, pages 393-403.
Crossref
Crossref
Sunny Kumar, Mouli Chatterjee, Pratyasha Ghosh, Kirat K. Ganguly, Malini Basu & Mrinal K. Ghosh. (2023) Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients. Genes & Diseases 10:4, pages 1318-1350.
Crossref
Crossref
Joanna Szpor, Joanna Streb, Anna Glajcar, Anna Streb-Smoleń, Agnieszka Łazarczyk, Paulina Korta, Karolina Brzuszkiewicz, Robert Jach & Diana Hodorowicz-Zaniewska. (2023) Dendritic Cell Subpopulations Are Associated with Morphological Features of Breast Ductal Carcinoma In Situ. International Journal of Molecular Sciences 24:12, pages 9918.
Crossref
Crossref
Gyöngyi Munkácsy, Libero Santarpia & Balázs Győrffy. (2023) Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer. International Journal of Molecular Sciences 24:8, pages 6945.
Crossref
Crossref
Hong-My Nguyen, Wyatt Paulishak, Mariam Oladejo & Laurence Wood. (2022) Dynamic tumor microenvironment, molecular heterogeneity, and distinct immunologic portrait of triple-negative breast cancer: an impact on classification and treatment approaches. Breast Cancer 30:2, pages 167-186.
Crossref
Crossref
Yanhui Zhu, Hongfei Zhang, Chaohu Pan, Gao He, Xiaoli Cui, Xiafei Yu, Xiaoqiang Zhang, Dongfang Wu, Junzhe Yang, Xian Wu, Haitao Luo & Xiaoan Liu. (2022) Integrated tumor genomic and immune microenvironment analysis identifies predictive biomarkers associated with the efficacy of neoadjuvant therapy for triple‐negative breast cancer. Cancer Medicine 12:5, pages 5846-5858.
Crossref
Crossref
Christina M. S. Hassing, Mathias Kvist Mejdahl, Anne-Vibeke Lænkholm, Niels Kroman, Ann Søegaard Knoop & Tove Holst Filtenborg Tvedskov. (2022) Adjuvant chemotherapy in patients with ER-negative/HER2-negative, T1abN0 breast cancer: a nationwide study. Breast Cancer Research and Treatment 198:1, pages 103-112.
Crossref
Crossref
Rajesh Pradhan, Anuradha Dey, Rajeev Taliyan, Anu Puri, Sanskruti Kharavtekar & Sunil Kumar Dubey. (2023) Recent Advances in Targeted Nanocarriers for the Management of Triple Negative Breast Cancer. Pharmaceutics 15:1, pages 246.
Crossref
Crossref
Talita Araújo B. da S. Santana, Larissa de Oliveira Passamai, Felipe Silva de Miranda, Thaiz Ferraz Borin, Grasiely Faccin Borges, Wilson Barros Luiz & Luciene Cristina Gastalho Campos. (2022) The Role of miRNAs in the Prognosis of Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. Diagnostics 13:1, pages 127.
Crossref
Crossref
Ji Li, Jiashuo Wu & Junwei Han. (2022) Analysis of Tumor Microenvironment Heterogeneity among Breast Cancer Subtypes to Identify Subtype-Specific Signatures. Genes 14:1, pages 44.
Crossref
Crossref
Nikolaos Spathas, Anna C. Goussia, Georgia-Angeliki Koliou, Helen Gogas, Flora Zagouri, Anna Batistatou, Antonia V. Charchanti, Alexandra Papoudou-Bai, Mattheos Bobos, Sofia Chrisafi, Kyriakos Chatzopoulos, Ioannis Kostopoulos, Triantafyllia Koletsa, Petroula Arapantoni, Dimitrios Pectasides, Eleni Galani, Angelos Koutras, George Zarkavelis, Emmanouil Saloustros, Dimitrios Bafaloukos, Charisios Karanikiotis, Iliada Bompolaki, Gerasimos Aravantinos, Amanda Psyrri, Evangelia Razis, Anna Koumarianou, Eleni Res, Helena Linardou & George Fountzilas. (2022) Association between CD8+ Tumor Infiltrating Lymphocytes and the Clinical Outcome of Patients with Operable Breast Cancer Treated with Adjuvant Dose-Dense Chemotherapy—A 10 Year Follow-Up Report of a Hellenic Cooperative Oncology Group Observational Study. Cancers 14:22, pages 5635.
Crossref
Crossref
Bin Qu, Yeming Han, Ting Liang, Chao Zhang, Guihua Hou & Feng Gao. (2022) Evaluation of a novel EphA2 targeting peptide for triple negative breast cancer based on radionuclide molecular imaging. Arabian Journal of Chemistry 15:11, pages 104211.
Crossref
Crossref
Angélique Bobrie, Océane Massol, Jeanne Ramos, Caroline Mollevi, Evelyne Lopez-Crapez, Nathalie Bonnefoy, Florence Boissière-Michot & William Jacot. (2022) Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast Cancer. Cancers 14:19, pages 4829.
Crossref
Crossref
Melitta B. Köpke, Marie-Christine Chateau, Florence Boissière-Michot, Mariella Schneider, Fabian Garrido, Alaleh Zati-Zehni, Theresa Vilsmaier, Mirjana Kessler, Nina Ditsch, Vincent Cavaillès & Udo Jeschke. (2022) Prognostic Relevance of Nuclear Receptors in Relation to Peritumoral Inflammation and Tumor Infiltration by Lymphocytes in Breast Cancer. Cancers 14:19, pages 4561.
Crossref
Crossref
Carlos Alexander Huertas-Caro, Mayra Alejandra Ramirez, Henry J. Gonzalez-Torres, María Carolina Sanabria-Salas & Silvia J. Serrano-Gómez. (2022) Immune Lymphocyte Infiltrate and its Prognostic Value in Triple-Negative Breast Cancer. Frontiers in Oncology 12.
Crossref
Crossref
Killian Onwudiwe, John Obayemi, Jingjie Hu, Josephine Oparah, Chinyerem Onyekanne, Chukwudalu Nwazojie, Toyin Aina, Vanessa Uzonwanne, Ali Salifu & Winston Soboyejo. (2021)
Investigation of creep properties and the cytoskeletal structures of
non‐tumorigenic
breast cells and
triple‐negative
breast cancer cells
. Journal of Biomedical Materials Research Part A 110:5, pages 1004-1020.
Crossref
Crossref
Izabela Orzołek, Jan Sobieraj & Joanna Domagała-Kulawik. (2022) Estrogens, Cancer and Immunity. Cancers 14:9, pages 2265.
Crossref
Crossref
Gilda Schmidt, Margit Maria Guhl, Erich-Franz Solomayer, Gudrun Wagenpfeil, Mohammed Eid Hammadeh, Ingolf Juhasz-Boess, Jan Endrikat, Mariz Kasoha & Rainer Maria Bohle. (2022) Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients. Archives of Gynecology and Obstetrics 306:5, pages 1689-1695.
Crossref
Crossref
Taylor Salisbury, Alisa Abozina, Ciro Zhang, Elaine Mao, Norbert Banyi, Joyce Leo, Diana Ionescu, Chen Zhou & Gang Wang. (2022) Histological subtype is associated with PD-L1 expression and CD8+ T-cell infiltrates in triple-negative breast carcinoma. Annals of Diagnostic Pathology 57, pages 151901.
Crossref
Crossref
Andrew W. Chung, Anthony J. Kozielski, Wei Qian, Jianying Zhou, Ann C. Anselme, Alfred A. Chan, Ping-Ying Pan, Delphine J. Lee & Jenny C. Chang. (2022) Tocilizumab overcomes chemotherapy resistance in mesenchymal stem-like breast cancer by negating autocrine IL-1A induction of IL-6. npj Breast Cancer 8:1.
Crossref
Crossref
Shuai Lin, Yi Zheng, Meng Wang, Linghui Zhou, Yuyao Zhu, Yujiao Deng, Ying Wu, Dai Zhang, Na Li, Huafeng Kang & Zhijun Dai. (2022) Associations of CXCL12 polymorphisms with clinicopathological features in breast cancer: a case-control study. Molecular Biology Reports 49:3, pages 2255-2263.
Crossref
Crossref
Jian Zheng, Yuntao Wei, Xiaoxi Li, Zhan Shen, Yong Zhang, Bo Huang, Youhong Jiang & Daqing Wang. (2022) Higher CD1a Levels Correlate with PD-L1 Expression and Predict Worse Overall Survival in Triple-Negative Breast Carcinoma. Breast Care 17:1, pages 31-39.
Crossref
Crossref
Cinzia Vetrei, Margherita Passariello, Guendalina Froechlich, Rosa Rapuano Lembo, Emanuele Sasso, Nicola Zambrano & Claudia De Lorenzo. (2021) Novel Combinations of Human Immunomodulatory mAbs Lacking Cardiotoxic Effects for Therapy of TNBC. Cancers 14:1, pages 121.
Crossref
Crossref
Roberto Lo Gullo, Hannah Wen, Jeffrey S. Reiner, Raza Hoda, Varadan Sevilimedu, Danny F. Martinez, Sunitha B. Thakur, Maxine S. Jochelson, Peter Gibbs & Katja Pinker. (2021) Assessing PD-L1 Expression Status Using Radiomic Features from Contrast-Enhanced Breast MRI in Breast Cancer Patients: Initial Results. Cancers 13:24, pages 6273.
Crossref
Crossref
Rodrigo Kern & Carolina Panis. (2021) CTLA-4 Expression and Its Clinical Significance in Breast Cancer. Archivum Immunologiae et Therapiae Experimentalis 69:1.
Crossref
Crossref
Yiyin Zhang, Qijiang Mao, Qiming Xia, Jiaxi Cheng, Zhengze Huang, Yirun Li, Peng Chen, Jing Yang, Xiaoxiao Fan, Yuelong Liang & Hui Lin. (2021) Noncoding RNAs link metabolic reprogramming to immune microenvironment in cancers. Journal of Hematology & Oncology 14:1.
Crossref
Crossref
Aalok Patwa, Rikiya Yamashita, Jin Long, Tyler Risom, Michael Angelo, Leeat Keren & Daniel L. Rubin. (2021) Multiplexed imaging analysis of the tumor-immune microenvironment reveals predictors of outcome in triple-negative breast cancer. Communications Biology 4:1.
Crossref
Crossref
Shuo Jia & Pingzhao Hu. (2021) ChrNet: A re-trainable chromosome-based 1D convolutional neural network for predicting immune cell types. Genomics 113:4, pages 2023-2031.
Crossref
Crossref
Filippo Borri & Annarita Granaglia. (2021) Pathology of triple negative breast cancer. Seminars in Cancer Biology 72, pages 136-145.
Crossref
Crossref
Semir Vranic, Farhan S. Cyprian, Zoran Gatalica & Juan Palazzo. (2021) PD-L1 status in breast cancer: Current view and perspectives. Seminars in Cancer Biology 72, pages 146-154.
Crossref
Crossref
Juan Zhang, Qi Tian, Mi Zhang, Hui Wang, Lei Wu & Jin Yang. (2021) Immune-related biomarkers in triple-negative breast cancer. Breast Cancer 28:4, pages 792-805.
Crossref
Crossref
Huihui Chen, Shijie Wu, Jun Hu, Kun Zhang, Kaimin Hu, Yuexin Lu, Jiapan He, Tao Pan & Yiding Chen. (2021) Prognostic Models for Nonmetastatic Triple-Negative Breast Cancer Based on the Pretreatment Serum Tumor Markers with Machine Learning. Journal of Oncology 2021, pages 1-13.
Crossref
Crossref
Majid Sharifi, Qian Bai, Mohammad Mahdi Nejadi Babadaei, Farhan Chowdhury, Mahbub Hassan, Akbar Taghizadeh, Hossein Derakhshankhah, Suliman Khan, Anwarul Hasan & Mojtaba Falahati. (2021) 3D bioprinting of engineered breast cancer constructs for personalized and targeted cancer therapy. Journal of Controlled Release 333, pages 91-106.
Crossref
Crossref
Ghada N. Al-Jussani, Tamara Z. Dabbagh, Dalia Al-Rimawi & Maher A. Sughayer. (2021) Expression of PD-L1 using SP142 CDx in triple negative breast cancer. Annals of Diagnostic Pathology 51, pages 151703.
Crossref
Crossref
Florence Boissière-Michot, Ghita Chabab, Caroline Mollevi, Séverine Guiu, Evelyne Lopez-Crapez, Jeanne Ramos, Nathalie Bonnefoy, Virginie Lafont & William Jacot. (2021) Clinicopathological Correlates of γδ T Cell Infiltration in Triple-Negative Breast Cancer. Cancers 13:4, pages 765.
Crossref
Crossref
Chun-Wen Cheng, Gwo-Tarng Sheu, Jing-Shiuan Chou, Pei-Han Wang, Yu-Chun Cheng & Chane-Yu Lai. (2021) Fine particulate matter PM2.5 generated by building demolition increases the malignancy of breast cancer MDA-MB-231 cells. Chemosphere 265, pages 129028.
Crossref
Crossref
Marta Garcia-Escolano, Yoel G. Montoyo-Pujol, Fernando Ortiz-Martinez, Jose J. Ponce, Silvia Delgado-Garcia, Tina A. Martin, Hortensia Ballester, F. Ignacio Aranda, Elena Castellon-Molla, J. Miguel Sempere-Ortells & Gloria Peiro. (2021) ID1 and ID4 Are Biomarkers of Tumor Aggressiveness and Poor Outcome in Immunophenotypes of Breast Cancer. Cancers 13:3, pages 492.
Crossref
Crossref
S.V. Vtorushin, N.V. Krakhmal & M.V. Zavyalova. (2021) Triple-negative breast cancer. Modern molecular genetic concepts and their clinical significance. Arkhiv patologii 83:3, pages 46.
Crossref
Crossref
Cong Jiang, Yubo Lu, Shiyuan Zhang & Yuanxi Huang. (2020) Systemic Immune-Inflammation Index Is Superior to Neutrophil to Lymphocyte Ratio in Prognostic Assessment of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. BioMed Research International 2020, pages 1-10.
Crossref
Crossref
Parisa Lotfinejad, Tohid Kazemi, Ahad Mokhtarzadeh, Dariush Shanehbandi, Farhad Jadidi Niaragh, Sahar Safaei, Milad Asadi & Behzad Baradaran. (2020) PD-1/PD-L1 axis importance and tumor microenvironment immune cells. Life Sciences 259, pages 118297.
Crossref
Crossref
Masanori Oshi, Stephanie Newman, Vijayashree Murthy, Yoshihisa Tokumaru, Li Yan, Ryusei Matsuyama, Itaru Endo & Kazuaki Takabe. (2020) ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer. Cancers 12:10, pages 2758.
Crossref
Crossref
Masanori Oshi, Mariko Asaoka, Yoshihisa Tokumaru, Li Yan, Ryusei Matsuyama, Takashi Ishikawa, Itaru Endo & Kazuaki Takabe. (2020) CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer. International Journal of Molecular Sciences 21:18, pages 6968.
Crossref
Crossref
Arthur Foulon, Pierrick Theret, Lise Rodat-Despoix & Philippe Kischel. (2020) Beyond Chemotherapies: Recent Strategies in Breast Cancer Treatment. Cancers 12:9, pages 2634.
Crossref
Crossref
Carlos López, Ramón Bosch-Príncep, Guifré Orero, Laia Fontoura Balagueró, Anna Korzynska, Marcial García-Rojo, Gloria Bueno, Maria del Milagro Fernández-Carrobles, Lukasz Roszkowiak, Cristina Callau Casanova, M. Teresa Salvadó-Usach, Joaquín Jaén Martínez, Albert Gibert-Ramos, Albert Roso-Llorach, Andrea Gras Navarro, Marta Berenguer-Poblet, Montse Llobera, Júlia Gil Garcia, Bárbara Tomás, Vanessa Gestí, Eeva Laine, Benoít Plancoulaine, Jordi Baucells & Maryléne Lejeune. (2020) Peritumoral immune infiltrates in primary tumours are not associated with the presence of axillary lymph node metastasis in breast cancer: a retrospective cohort study. PeerJ 8, pages e9779.
Crossref
Crossref
Sina Abdkarimi, Saiedeh Razi Soofiyani, Goli Elham, Hossein Mashhadi Abdolahi, Elham Safarzadeh & Behzad Baradaran. (2020) Targeting immune checkpoints: Building better therapeutic puzzle in pancreatic cancer combination therapy. European Journal of Cancer Care 29:5.
Crossref
Crossref
Yajie Zhao, Chunrui Pu & Zhenzhen Liu. (2020) Exploration the Significance of a Novel Immune-Related Gene Signature in Prognosis and Immune Microenvironment of Breast Cancer. Frontiers in Oncology 10.
Crossref
Crossref
Meiling Huang, Jiang Wu, Rui Ling & Nanlin Li. (2020) Quadruple negative breast cancer. Breast Cancer 27:4, pages 527-533.
Crossref
Crossref
Jen-Hwey Chiu, Ling-Ming Tseng, Tzu-Ting Huang, Chun-Yu Liu, Jir-You Wang, Ching-Po Huang, Yi-Fang Tsai & Chih-Yi Hsu. (2020) MEGF11 is related to tumour recurrence in triple negative breast cancer via chemokine upregulation. Scientific Reports 10:1.
Crossref
Crossref
Eric C. LaCasse. (2020) Taking aim with IAP antagonists at triple-negative breast cancer: a moving target no more?. Cell Death & Disease 11:5.
Crossref
Crossref
Jennifer R. Baker, Jennette A. Sakoff & Adam McCluskey. (2019) The aryl hydrocarbon receptor (AhR) as a breast cancer drug target. Medicinal Research Reviews 40:3, pages 972-1001.
Crossref
Crossref
Shima Bastaki, Mahzad Irandoust, Armin Ahmadi, Mohammad Hojjat-Farsangi, Patrick Ambrose, Shahin Hallaj, Mahdi Edalati, Ghasem Ghalamfarsa, Gholamreza Azizi, Mehdi Yousefi, Hengameh Chalajour & Farhad Jadidi-Niaragh. (2020) PD-L1/PD-1 axis as a potent therapeutic target in breast cancer. Life Sciences 247, pages 117437.
Crossref
Crossref
Connie Kang & Yahiya Y. Syed. (2020) Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer. Drugs 80:6, pages 601-607.
Crossref
Crossref
Carlos López, Ramon Bosch, Guifre Orero, Anna Korzynska, Marcial García-Rojo, Gloria Bueno, María del Milagro Fernández-Carrobles, Albert Gibert-Ramos, Lukasz Roszkowiak, Cristina Callau, Laia Fontoura, Maria-Teresa Salvadó, Tomás Álvaro, Joaquín Jaén, Albert Roso-Llorach, Montserrat Llobera, Julia Gil, Montserrat Onyos, Benoît Plancoulaine, Jordi Baucells & Marylène Lejeune. (2020) The Immune Response in Nonmetastatic Axillary Lymph Nodes Is Associated with the Presence of Axillary Metastasis and Breast Cancer Patient Outcome. The American Journal of Pathology 190:3, pages 660-673.
Crossref
Crossref
Weiqiang Jing, Xing Guo, Ganyu Wang, Yuxuan Bi, Lihui Han, Qingfen Zhu, Chunhong Qiu, Masato Tanaka & Yunxue Zhao. (2020) Breast cancer cells promote CD169+ macrophage-associated immunosuppression through JAK2-mediated PD-L1 upregulation on macrophages. International Immunopharmacology 78, pages 106012.
Crossref
Crossref
Ling Deng, Donghao Lu, Yingnan Bai, Yanping Wang, Hong Bu & Hong Zheng. (2019) Immune Profiles of Tumor Microenvironment and Clinical Prognosis among Women with Triple-Negative Breast Cancer. Cancer Epidemiology, Biomarkers & Prevention 28:12, pages 1977-1985.
Crossref
Crossref
Wenfa Huang, Ran Ran, Bin Shao & Huiping Li. (2019) Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis. Breast Cancer Research and Treatment 178:1, pages 17-33.
Crossref
Crossref
Isabelle Valo, Pedro Raro, Alice Boissard, Amine Maarouf, Pascal Jézéquel, Véronique Verriele, Mario Campone, Olivier Coqueret & Catherine Guette. (2019) OLFM4 Expression in Ductal Carcinoma In Situ and in Invasive Breast Cancer Cohorts by a SWATH‐Based Proteomic Approach. PROTEOMICS 19:21-22.
Crossref
Crossref
Margherita Passariello, Anna Morena D’Alise, Annachiara Esposito, Cinzia Vetrei, Guendalina Froechlich, Elisa Scarselli, Alfredo Nicosia & Claudia De Lorenzo. (2019) Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling. Scientific Reports 9:1.
Crossref
Crossref
Ping Liu, Qing Xiao, Bing Zhou, Zhehao Dai & Yijun Kang. (2019) Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma. World Neurosurgery 129, pages e240-e254.
Crossref
Crossref
Alexandre de Nonneville, Pascal Finetti, José Adelaide, Éric Lambaudie, Patrice Viens, Anthony Gonçalves, Daniel Birnbaum, Emilie Mamessier & François Bertucci. (2019) A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers. Cancers 11:8, pages 1158.
Crossref
Crossref
Rachel L. Stewart, Katherine L. Updike, Rachel E. Factor, N. Lynn Henry, Kenneth M. Boucher, Philip S. Bernard & Katherine E. Varley. (2019) A Multigene Assay Determines Risk of Recurrence in Patients with Triple-Negative Breast Cancer. Cancer Research 79:13, pages 3466-3478.
Crossref
Crossref
Rama Soundararajan, Jared Fradette, Jessica Konen, Stacy Moulder, Xiang Zhang, Don Gibbons, Navin Varadarajan, Ignacio Wistuba, Debasish Tripathy, Chantale Bernatchez, Lauren Byers, Jeffrey Chang, Alejandro Contreras, Bora Lim, Edwin Parra, Emily Roarty, Jing Wang, Fei Yang, Michelle Barton, Jeffrey Rosen & Sendurai Mani. (2019) Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. Cancers 11:5, pages 714.
Crossref
Crossref
Junnan Xu, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao & Tao Sun. (2019) Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor‑negative or human epidermal growth factor receptor 2‑positive breast cancer. Oncology Letters.
Crossref
Crossref
Andrea Bizzego, Nicole Bussola, Marco Chierici, Valerio Maggio, Margherita Francescatto, Luca Cima, Marco Cristoforetti, Giuseppe Jurman & Cesare Furlanello. (2019) Evaluating reproducibility of AI algorithms in digital pathology with DAPPER. PLOS Computational Biology 15:3, pages e1006269.
Crossref
Crossref
Meijuan Zhang & ShengFeng Qiu. (2019) Activation of GPR120 promotes the metastasis of breast cancer through the PI3K/Akt/NF-κB signaling pathway. Anti-Cancer Drugs 30:3, pages 260-270.
Crossref
Crossref
Kang Wang, Hai‐Lin Li, Yong‐Fu Xiong, Yang Shi, Zhu‐Yue Li, Jie Li, Xiang Zhang & Hong‐Yuan Li. (2019) Development and validation of nomograms integrating immune‐related genomic signatures with clinicopathologic features to improve prognosis and predictive value of triple‐negative breast cancer: A gene expression‐based retrospective study. Cancer Medicine 8:2, pages 686-700.
Crossref
Crossref
Yuichiro Miyoshi, Tadahiko Shien, Akiko Ogiya, Naoko Ishida, Kieko Yamazaki, Rie Horii, Yoshiya Horimoto, Norikazu Masuda, Hiroyuki Yasojima, Touko Inao, Tomofumi Osako, Masato Takahashi, Nobumoto Tomioka, Yumi Wanifuchi‑Endo, Mitsuchika Hosoda, Hiroyoshi Doihara & Hiroko Yamashita. (2018) Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor‑positive/human epidermal growth factor receptor type 2 negative breast cancer. Oncology Letters.
Crossref
Crossref
T. N. Zabotina, O. V. Korotkova, A. I. Chertkova, E. N. Zakharova, D. V. Tabakov, N. T. Dzhgamadze, M. V. Savostikova, E. V. Artamonova, V. A. Khailenko, E. I. Kovalenko & Z. G. Kadagidze. (2018) Tumor-Infiltrating Lymphocytes in Breast Cancer. Association with Clinical and Pathological Parameters. Bulletin of Experimental Biology and Medicine 166:2, pages 241-244.
Crossref
Crossref
Xiaoli Zhou, Lizhou Jia, Yangyang Sun, Lingyun Xu, Xudong Wang & Qi Tang. (2018) Sperm‑associated antigen 5 is a potential biomarker for poor prognosis in breast cancer. Oncology Letters.
Crossref
Crossref
Neal Shah, Afroz S. Mohammad, Pushkar Saralkar, Samuel A. Sprowls, Schuyler D. Vickers, Devin John, Rachel M. Tallman, Brandon P. Lucke-Wold, Katherine E. Jarrell, Mark Pinti, Richard L. Nolan & Paul R. Lockman. (2018) Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases. Pharmacological Research 132, pages 47-68.
Crossref
Crossref
Kyung Do ByunHyo Jun HwangKi Jae ParkMin Chan KimSe Heon ChoMi Ha JuJin Hwa LeeJin Sook Jeong. (2018) T-Cell Immunoglobulin Mucin 3 Expression on Tumor Infiltrating Lymphocytes as a Positive Prognosticator in Triple-Negative Breast Cancer. Journal of Breast Cancer 21:4, pages 406.
Crossref
Crossref
A. Z. Aikian & I. P. Kaidashev. (2018) QUANTITATIVE CHARACTERISTICS OF CD68+ AND CD163+ MACROPHAGES IN THE PRIMARY FOCUS AND IN METASTATIC LESIONS OF REGIONAL LYMPH NODES IN TRIPLE-NEGATIVE INVASIVE BREAST CARCINOMA. Bulletin of Problems Biology and Medicine 2:4, pages 313.
Crossref
Crossref